Literature DB >> 9542927

Utility of major leukocyte subpopulations for monitoring secondary cytomegalovirus infections in renal-allograft recipients by PCR.

P Schäfer1, W Tenschert, L Cremaschi, K Gutensohn, R Laufs.   

Abstract

The feasibility of the major peripheral blood leukocyte (PBL) subsets for use in qualitative and quantitative PCR to monitor secondary cytomegalovirus (CMV) infection and ganciclovir therapy was assessed with 188 blood samples derived from 40 CMV immunoglobulin G-positive renal-allograft recipients. In pp65 antigen-positive patients all leukocyte fractions, but only 79.5% of plasma preparations, were PCR positive. In pp65 antigen-negative samples from patients after antiviral treatment only 7.3% of polymorphonuclear cell (PMNL) samples, but 81.8% of peripheral blood mononuclear cells (PBMC), and 10.9% of plasma samples remained PCR positive. Similarly, in patients with latent infections only 5.0% of PMNL, but 51.7% of PBMC preparations, and 8.0% of plasma samples were PCR positive. Regarding patients with active CMV infection, CMV DNA copy numbers in PMNL correlated significantly with pp65 antigen-positive cell counts before and after onset of ganciclovir therapy. Significant differences in CMV DNA copy numbers in PMNL and plasma were observed (i) between patients with symptomatic infection and those with asymptomatic infection and (ii) between patients with active infection and those with latent infection. In contrast, PBMC harbored equally low CMV DNA levels both in patients with active infection and those with latent infections, and no decline of CMV DNA load in PBMC was observed during antiviral treatment. We conclude that detection of CMV DNA in PMNL, not in PBMC, is associated with active infections and is more sensitive than detection of CMV DNA in plasma. Negative PCR results for PMNL after antiviral therapy indicate recovery, and fewer unwanted positive results occur compared to PBMC and plasma. Therefore, purified PMNL should be preferred for analysis by qualitative CMV PCR to avoid unwanted positive results. The CMV DNA load in PBMC compared with that in PMNL is negligible during active infection, so mixed PBL are sufficient for use in quantitative PCR.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9542927      PMCID: PMC104679          DOI: 10.1128/JCM.36.4.1008-1014.1998

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  41 in total

1.  Low predictive value of polymerase chain reaction for diagnosis of cytomegalovirus disease in liver transplant recipients.

Authors:  R Delgado; C Lumbreras; C Alba; M A Pedraza; J R Otero; R Gómez; E Moreno; A R Noriega; C V Payá
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

2.  Quantitative PCR: the determination of template copy numbers by temperature gradient gel electrophoresis (TGGE).

Authors:  K Henco; M Heibey
Journal:  Nucleic Acids Res       Date:  1990-11-25       Impact factor: 16.971

3.  Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease.

Authors:  M Shinkai; S A Bozzette; W Powderly; P Frame; S A Spector
Journal:  J Infect Dis       Date:  1997-02       Impact factor: 5.226

4.  Persistence of cytomegalovirus in mononuclear cells in peripheral blood from blood donors.

Authors:  P Stanier; D L Taylor; A D Kitchen; N Wales; Y Tryhorn; A S Tyms
Journal:  BMJ       Date:  1989-10-07

5.  Localization of human cytomegalovirus in peripheral blood leukocytes by in situ hybridization.

Authors:  W M Dankner; J A McCutchan; D D Richman; K Hirata; S A Spector
Journal:  J Infect Dis       Date:  1990-01       Impact factor: 5.226

6.  Interactions of human cytomegalovirus with leukocytes in vivo: analysis by in situ hybridization.

Authors:  L W Turtinen; R Saltzman; M C Jordan; A T Haase
Journal:  Microb Pathog       Date:  1987-10       Impact factor: 3.738

7.  Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells.

Authors:  J Taylor-Wiedeman; J G Sissons; L K Borysiewicz; J H Sinclair
Journal:  J Gen Virol       Date:  1991-09       Impact factor: 3.891

8.  Development and clinical significance of a diagnostic assay based on the polymerase chain reaction for detection of human cytomegalovirus DNA in blood samples from immunocompromised patients.

Authors:  D Zipeto; M G Revello; E Silini; M Parea; E Percivalle; M Zavattoni; G Milanesi; G Gerna
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

9.  Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia.

Authors:  G Gerna; M G Revello; E Percivalle; F Morini
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

10.  Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus.

Authors:  M P Cranage; T Kouzarides; A T Bankier; S Satchwell; K Weston; P Tomlinson; B Barrell; H Hart; S E Bell; A C Minson
Journal:  EMBO J       Date:  1986-11       Impact factor: 11.598

View more
  10 in total

1.  Errors in published sequences of human cytomegalovirus primers and probes: do we need more quality control?

Authors:  Wafa Habbal; Fawza Monem; Barbara Christine Gärtner
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

2.  Human cytomegalovirus DNA in plasma and serum specimens of renal transplant recipients is highly fragmented.

Authors:  René Boom; Cees J A Sol; Tim Schuurman; Alex Van Breda; Jan F L Weel; Marcel Beld; Ineke J M Ten Berge; Pauline M E Wertheim-Van Dillen; Menno D De Jong
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

3.  Risk of congenital cytomegalovirus infection among HIV-exposed uninfected infants is not decreased by maternal nelfinavir use during pregnancy.

Authors:  Soren Gantt; Erin Leister; Denise L Jacobsen; Isabelle Boucoiran; Meei-Li Huang; Keith R Jerome; Gonzague Jourdain; Nicole Ngo-Giang-Huong; Sandra Burchett; Lisa Frenkel
Journal:  J Med Virol       Date:  2015-11-18       Impact factor: 2.327

Review 4.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

5.  False-positive results of plasma PCR for cytomegalovirus DNA due to delayed sample preparation.

Authors:  P Schäfer; W Tenschert; M Schröter; K Gutensohn; R Laufs
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

Review 6.  Viral infections of the gastrointestinal tract.

Authors:  R W Goodgame
Journal:  Curr Gastroenterol Rep       Date:  1999-08

Review 7.  Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation.

Authors:  Raymund R Razonable; Randall T Hayden
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

8.  Monitoring human cytomegalovirus infection with nested PCR: comparison of positive rates in plasma and leukocytes and with quantitative PCR.

Authors:  Shu Zhang; Yi-Hua Zhou; Lei Li; Yali Hu
Journal:  Virol J       Date:  2010-04-15       Impact factor: 4.099

9.  Multiplex, quantitative, real-time PCR assay for cytomegalovirus and human DNA.

Authors:  Jason L Sanchez; Gregory A Storch
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

10.  Chronic lymphocytic leukemia patients have a preserved cytomegalovirus-specific antibody response despite progressive hypogammaglobulinemia.

Authors:  Katrina Vanura; Franz Rieder; Marie-Theres Kastner; Julia Biebl; Michael Sandhofer; Trang Le; Robert Strassl; Elisabeth Puchhammer-Stöckl; Thomas Perkmann; Christoph F Steininger; Kostas Stamatopoulos; Wolfgang Graninger; Ulrich Jäger; Christoph Steininger
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.